Mylan (MYL) Receives Favorable PTO Verdict for Third Copaxone IPR (TEVA)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/25/2024
- S&P 500 ends higher as markets weigh rising yields, upbeat corporate results
- Meta Platforms reports softer Q2 revenue guidance on plans to boost spending on AI
- IBM (IBM) announces mixed Q1 results, HashiCorp acquisition; shares down
- Equities mixed as investors eye earnings; yen on intervention watch
- ServiceNow (NOW) stock falls as refreshed subscription outlook trails estimates
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Hasbro (HAS) brand strength sees earnings top expectations
- IBM (IBM) announces mixed Q1 results, HashiCorp acquisition; shares down
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Crude Inventory Declined 6.4 Million Barrels Last Week
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
UPDATE: Teva's (TEVA) '302 Capaxone Patent Invalidated by U.S. Patent Office
September 1, 2016 2:42 PM EDT(Updated - September 1, 2016 2:51 PM EDT)
Teva Pharma (NYSE: TEVA) lost a third court ruling against Mylan (NASDAQ: MYL) related to Teva's drug Copaxone. Today's decision by the U.S. Patent and Trademark Office stated that claims 1-12 of the 302 patent are held unpatentable. Previously two other patents were invalidated.
... MoreUPDATE: MannKind (MNKD) May Not Be Able to Compete with Mylan's (MYL) EpiPen; Co. to Raise $10M - Feuerstein
August 31, 2016 1:37 PM EDT(Updated - August 31, 2016 1:50 PM EDT)
MannKind's (NASDAQ: MNKD) inhaled epinephrine may not be competition for Mylan's (NASDAQ: MYL) EpiPen, according to critic Adam Feurstein of theStreet. Earlier gains were tied to a NewTimes... More
